Abdullah Albassam

Dr. Abdullah Albassam


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAbdullah Albassam
Abdullah Albassam
SAShahad Alshammari
Shahad Alshammari
GOGhadeer Ouda
Ghadeer Ouda
SKSamuel Koshy
Samuel Koshy
AAAbdelmoneim Awad
Abdelmoneim Awad
Pharmacogenetics practice has been successfully implemented in many developed countries to enhance personalized medicine and improve clinical and economic outcomes. An understanding of healthcare providers’ knowledge, perceptions, confidence towards pharmacogenetics, and their active enrollment with pharmacogenetic testing is essential for test acceptance and utilization. This study was designed to assess physicians’ and pharmacists’ knowledge, perceptions, and confidence towards pharmacogenetics, determine the preferred learning format for their future education in pharmacogenetics, and identify the barriers to its application in their practice settings. A cross-sectional survey was conducted using a pretested self-administered questionnaire on a sample of 629 randomly selected physicians and pharmacists. Descriptive and comparative analyses were used in data analysis. The response rate was 98.1%. Less than one-tenth of respondents were exposed to pharmacogenetics education or training (8.9%), applied pharmacogenetics testing in their practice (9.4%), or provided patient counselling on the results of the pharmacogenetic testing (9.1%), and over 90% of them were physicians. The overall respondents’ mean (SD) total knowledge score percentage was low [45.0% (24)] and there was no significant difference between the physicians and pharmacists scores (p>0.05). Only 16.0% of participants indicated that they felt confident in applying pharmacogenetics in their practice settings. Despite these low levels of knowledge and self-confidence, 70.2% of participants expressed overall positive perceptions towards pharmacogenetics and its clinical implications. These positive overall perceptions were found to be significantly more common among pharmacists compared to physicians (p<0.05). The top two perceived barriers facing the implementation of pharmacogenetics in Kuwait were lack of education or training and clinical guidelines. These findings highlight important concerns and will aid in the assessment of current pharmacogenetics practice. Also, they will provide further insight in designing future targeted multifaceted interventions to promote the adoption and utilization of pharmacogenetics testing in Kuwait.

20 July 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAbdullah Albassam
Abdullah Albassam
HAHamad Almohammed
Hamad Almohammed
MAMalak Alhujaili
Malak Alhujaili
SKSamuel Koshy
Samuel Koshy
AAAbdelmoneim Awad
Abdelmoneim Awad
Collaborative practice between physicians and pharmacists has a positive effect on healthcare outcomes. Understanding the local data related to this collaboration is vital in establishing efficient collaboration. Therefore, this study was designed to assess the collaborative relationships between physicians and pharmacists working in the primary healthcare centres regarding their attitudes and experiences, preferred methods of communication, perceptions related to the role of pharmacists, areas of potential further collaboration, and perceived barriers. A cross-sectional study was conducted using two parallel pretested self-administered questionnaires on a sample of 518 randomly selected physicians and pharmacists. Descriptive and comparative analyses were used in data analysis. The overall response rate was 86.3%. Although over 98% of respondents agreed that physician-pharmacist collaboration improves patient outcomes, more than half of the physicians (52.1%) and pharmacists (55.7%) had never practised collaboratively. Both groups preferred to communicate face-to-face (76.7%) or via telephone (76.5%). Both professions showed good agreement on pharmacists’ roles related to managing side effects, improving adherence, assisting in dosage adjustment, providing advice regarding drug interactions, and providing drug information to physicians. They indicated disagreements on the importance of dispensing of prescriptions and providing advice to physicians regarding modification of drug therapy. Both groups expressed overall positive perceptions of the potential for further collaboration in areas related to the clinical roles of pharmacists, which were significantly higher among those with practice experience of < 10 years and those aged < 40 years (p<0.05). The top four perceived barriers to collaborative practice were lack of time (84.1%), lack of financial compensation (76.3%), lack of face-to-face communication (68.9%), and the possible fragmentation of patient care by the involvement of multiple healthcare professionals (68.9%). The present findings provide valuable input that could be a catalyst to enhance or establish physician-pharmacist collaboration in primary healthcare settings in Kuwait.

1 June 2020 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
AAAbdullah Albassam
Abdullah Albassam
AAAmal Alharbi
Amal Alharbi
AAAhmed Awaisu
Ahmed Awaisu
Purpose: Inhaled corticosteroids (ICS) are the mainstay maintenance therapy for asthma management. Non-adherence to ICS, which can lead to exacerbations and poor asthma control, is commonly reported among adult patients with asthma. The level of adherence to ICS among adult patients with asthma in Kuwait has not been previously published. The aim of this study was to assess adherence to ICS among adults with asthma in Kuwait. Patients and Methods: A cross-sectional study was conducted among adult patients with asthma using ICS therapy at ambulatory asthma clinics in Kuwait. Adherence to ICS was assessed using the Medication Adherence Report Scale for Asthma (MARS-A). Descriptive and logistic regression analyses were conducted using SPSS version 23. Results: One hundred and forty-nine patients with a mean age of 41.42 (12.75) years participated in the study. The majority of the participants (82.6%) reported low adherence to ICS. Approximately, three-quarters of the participants reported that they used ICS either when needed or when they felt breathless. Furthermore, about half of them admitted that they tried to avoid using ICS (46.3%), or forgot to take ICS (51%), or only used ICS before performing an exercise that made them breathless (54%). In the multivariate logistic regression analysis, independent predictors (age, education, and smoking status) were not found to significantly influence the overall adherence to ICS therapy. Conclusion: Adherence to ICS among adult patients with asthma was found to be low in ambulatory care settings in Kuwait. Future studies should aim to determine the barriers to ICS adherence among patients with asthma, with a focus on developing effective intervention strategies.

24 April 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DADerar H. Abdel-Qader
Derar H. Abdel-Qader
AAAbdullah Albassam
Abdullah Albassam
ETEsra Taybeh
Esra Taybeh
NMNadia Al Mazrouei
Nadia Al Mazrouei
SMSara Murad Albarkat Meer
Sara Murad Albarkat Meer
SASalahdein AbuRuz
Salahdein AbuRuz
Objectives: Schizophrenia, unipolar depression, bipolar disorder, bipolar mania, and bipolar depression are a few of the severe psychiatric diseases that affect millions of individuals and their overall life quality. This study aimed to look at differences in TGA, TC, HDL, LDL, and FPG levels in people who were going through acute episodes of listed diseases. Materials and methods: A cross-sectional prospective study was carried out in Jordan between January and November of 2023, involving all patients with the aforementioned diseases who attended three psychiatric clinics. This study encompassed results from 1187 patients (women N = 675, 56.87%) who were classified into the following ranges: 65. Results: The average level of LDL was the highest in bipolar depression (112.442 ± 36.178 mg/dL) and the lowest in bipolar mania (111.25 ± 33.14 mg/dL). The average level of HDL was the highest in schizophrenia (58.755 ± 16.198 mg/dL) and the lowest in bipolar depression (45.584 ± 12.128 mg/dL). Both average levels of TC and TGA were the highest in patients with bipolar depression (188.403 ± 37.396 mg/dL and 149.685 ± 96.951 mg/dL, respectively) and the lowest in bipolar mania (164.790 ± 40.488 mg/dL and 100.679 ± 54.337 mg/dL, respectively). The average level of FPG was the highest in unipolar depression (94.00 ± 21.453 mg/dL) and the lowest in bipolar mania (89.492 ± 14.700 mg/dL). Conclusions: The results confirmed that lipid and glucose abnormalities were more common in people with schizophrenia and mood disorders (unipolar and bipolar).

28 September 2025 in Pharmacy
Verified
Journal Article
Open access
PDF file
DADerar H. Abdel-Qader
Derar H. Abdel-Qader
KAKhalid Awad Al-kubaisi
Khalid Awad Al-kubaisi
ETEsra Taybeh
Esra Taybeh
NMNadia Al Mazrouei
Nadia Al Mazrouei
RIRana M. Ibrahim
Rana M. Ibrahim
AAAbdullah Albassam
Abdullah Albassam
Introduction: Drug–drug interactions (DDI) are a major, preventable cause of patient harm, a challenge amplified in Jordan by rising polypharmacy and documented high rates of medication errors. To date, no study in Jordan has systematically compared hospital and community pharmacists. This study aimed to conduct the first national, comparative assessment of DDI management among these two cadres. Materials and Methods: A national, cross-sectional study was conducted with 380 licensed pharmacists (175 hospitals, 205 community) recruited via proportionate stratified random sampling. A validated online questionnaire assessed demographics, objective DDI knowledge, professional attitudes, practices, and barriers. Multivariable logistic regression was used to identify independent predictors of high knowledge and optimal practice. All collected data were coded, cleaned, and analyzed using the Statistical Package for the Social Sciences (SPSS V28.0). Results: Hospital pharmacists achieved significantly higher mean objective knowledge scores than community pharmacists (10.3 vs. 8.1 out of 15, p < 0.001), a gap particularly wide for interactions involving high-risk OTC medications. The primary barrier for community pharmacists was a lack of access to patient data (85.4%), contrasting with high workload and physician resistance in hospitals. Optimal practice was independently predicted by higher knowledge (AOR = 1.25), a hospital practice setting (AOR = 3.65), and was inhibited by perceived physician resistance (AOR = 0.45). Conclusions: Jordanian hospital and community pharmacists operate in distinct worlds of knowledge and practice. A tailored, dual-pronged national strategy is essential. For hospitals, interventions should target interprofessional dynamics. For community pharmacies, health policy reform to provide access to integrated patient data is the most urgent priority. These findings highlight a globally relevant challenge of practice-setting disparities, offering a model for other nations to develop tailored, context-specific interventions to improve medication safety.

21 May 2026 in Pharmacy
Verified
Journal Article
Open access
PDF file
DADerar H. Abdel-Qader
Derar H. Abdel-Qader
NMNadia Al Mazrouei
Nadia Al Mazrouei
ETEsra Taybeh
Esra Taybeh
RIRana M. Ibrahim
Rana M. Ibrahim
AAAbdullah Albassam
Abdullah Albassam
SAShorouq Al-Omoush
Shorouq Al-Omoush
Tobacco use remains a major public health challenge in Jordan, where cigarette smoking and waterpipe use are both common and dual use is increasingly prevalent. Community pharmacies are highly accessible healthcare settings, yet structured smoking-cessation services remain underutilized. This study evaluated the clinical effectiveness and implementation of Dual-Quit Digital, a pharmacist-delivered cessation counseling program tailored to the type of tobacco used, paired with a 6-month automated WhatsApp® (Menlo Park, CA, USA) follow-up system. We conducted a pragmatic, two-arm, parallel-group, Hybrid Type 2 cluster randomized controlled trial in 16 community pharmacies in Jordan, randomized 1:1 to intervention or usual care. A total of 320 adult tobacco users were enrolled (160 per arm). The intervention combined a structured in-pharmacy pharmacist consultation, tailored behavioral support, phenotype-stratified pharmacotherapy support, and 6 months of semi-automated WhatsApp® follow-up with telepharmacy escalation for predefined red-flag responses. The control arm received usual care, consisting of opportunistic brief advice and standard over-the-counter sales without proactive follow-up. The primary outcome was biochemically verified continuous abstinence at 6 months, defined as exhaled carbon monoxide (CO) < 10 ppm and analyzed using intention-to-treat principles. Secondary outcomes included 7-day point prevalence abstinence (PPA) at 3 and 6 months, 30-day PPA at 6 months, both-product abstinence among baseline dual users, pharmacotherapy uptake and adherence, and implementation-relevant outcomes, including service reach, feasibility of recruitment, and digital engagement metrics. All 16 pharmacies were retained, and all 320 randomized participants were included in the intention-to-treat analysis. At 6 months, CO-verified continuous abstinence was achieved by 26.3% of participants in the intervention arm compared with 11.3% in the control arm (adjusted odds ratio [aOR] 2.84, 95% CI 1.55–5.18; p < 0.001). The intervention also improved 7-day PPA at 3 months (33.1% vs. 15.6%; aOR 2.68, 95% CI 1.56–4.60; p < 0.001), 7-day PPA at 6 months (30.6% vs. 14.4%; aOR 2.62, 95% CI 1.48–4.62; p = 0.001), and 30-day PPA at 6 months (28.1% vs. 11.9%; aOR 2.89, 95% CI 1.59–5.24; p < 0.001). Among baseline dual users, both-product abstinence was higher in the intervention arm (21.9% vs. 7.8%; aOR 3.30, 95% CI 1.12–9.75; p = 0.026). Pharmacotherapy initiation was more frequent in the intervention arm (72.5% vs. 28.1%; p < 0.001), as was self-reported adherence for at least 8 weeks among initiators (56.0% vs. 26.7%; p = 0.002). In the intervention arm, active patient response rates to scheduled WhatsApp® messages remained substantial, with 88.1% responding at Week 1, 73.8% at Week 4, 67.5% at Month 3, and 61.3% at Month 6; 145 red-flag triggers were captured from 62 participants, and 84.1% of escalations resulted in successful pharmacist follow-up within 48 h. The Dual-Quit Digital model significantly improved smoking-cessation outcomes compared with usual care and proved operationally feasible. These findings support integrating phenotype-stratified pharmacist counselling, pharmacotherapy support, and low-burden digital follow-up as a pragmatic cessation model for Jordan and similar settings.